Polartechnics EGM to proceed despite Opara's request to postpone
11 August, 2005 by Ruth BeranA Polartechnics (ASX:PLT) extraordinary general meeting (EGM) requisitioned by the company's former interim chairman Richard Opara will be held in Sydney this Friday, despite the company receiving a letter from him on August 8 proposing to postpone the meeting.
Relenza order report leaves Biota mystified
11 August, 2005 by Iain ScottBiota Holdings (ASX:BTA) has backed as "accurate" a newspaper report that Germany has placed an order of more than AUD$100 million for Relenza, the anti-flu drug developed by Biota and commercialised by GlaxoSmithKline.
C3 raises $10m
11 August, 2005 by Ruth BeranPerth-based Clinical Cell Culture (C3, ASX:CCE) has placed 28.6 million new fully paid ordinary shares worth AUD$10 million with Australian institutional and sophisticated investors.
NZ's AgVax acquired by Dutch firm Intervet
11 August, 2005 by Helen SchullerNew Zealand-based animal vaccine specialist AgVax Developments has been taken over by Intervet, a business unit of Dutch healthcare giant Akzo Nobel.
EvoGenix lists at 20 per cent premium
11 August, 2005 by Ruth BeranAntibody therapeutic developer EvoGenix (ASX:EGX) listed today on the Australian Stock Exchange at AUD$0.30, 20 per cent above its issue price of AUD$0.25.
Select Vaccines out-licenses hepatitis A diagnostic test
10 August, 2005 by Ruth BeranSelect Vaccines (ASX:SLT) has licensed the manufacture, global marketing and distribution of its rapid hepatitis A diagnostic technology to US-based Rapid Medical Diagnostic (RMD), but has kept the distribution rights for the test in Australia and New Zealand.
Avexa ends year with two years' cash in the bank
10 August, 2005 by Ruth BeranMelbourne-based biotech Avexa (ASX:AVX) has finished its first financial year of operation with AUD$15.7 million in the bank -- enough operating cash for two years, according to CEO Julian Chick .
Apollo claims competitive advantage
10 August, 2005 by Ruth BeranRecently listed Sydney biopharma Apollo Life Sciences (ASX:AOP) has claimed that its human-expressed vascular endothelial growth factor (VEGF), a protein involved in the formation of new blood vessels, performs five times better in an international proliferation test than a leading competitor's protein and the World Health Organisation's (WHO) protein standard.
Prima to gain full ownership of its four subsidiaries
09 August, 2005 by Ruth BeranPrima Biomed (ASX:PRR) and the Austin Research Institute (ARI) have reached an in principle agreement enabling Prima to gain full ownership of its four subsidiary companies, Oncomab, Panvax, Cancer Vac and Arthron.
Progen to collaborate with Sanofi-Aventis on prostate cancer trials
09 August, 2005 by Ruth BeranBrisbane cancer drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) will expand its phase II clinical trial program into prostate cancer to assess the efficacy and safety of its PI-88 angiogenesis inhibitor in combination with Sanofi-Aventis' chemotherapy agent Taxotere (docetaxel).
Bottom-line boost for LCT
09 August, 2005 by Graeme O'NeillA week after revealing spectacular preclinical results from its novel NeurotropinCell therapy for Huntington's disease, Auckland-based cell-therapy specialist Living Cell Technologies (ASX:LCT) has announced a therapeutic injection in its bottom line, after a successful capital raising pumped AUD$2.3 million into its coffers.
GTG sports gene test to be distributed in Japan
08 August, 2005 by Ruth BeranMelbourne-based Genetic Technologies (ASX:GTG) has signed an agreement with health and lifestyle industry supplier Sportsstyle for the marketing and distribution of its ACTN3 SportsGene Test throughout Japan.
Bio-Layer plans backdoor listing
08 August, 2005 by Ruth BeranBrisbane-based materials science specialist Bio-Layer is planning a backdoor listing on the ASX through SSH Medical (ASX:SSH) in September, aiming to raise between $3.5 and $5 million in capital to commercialise its products.
Alchemia named Queensland's 'smartest' company
05 August, 2005 by Helen SchullerBrisbane biopharma Alchemia (ASX:ACL) has been named the overall winner of the Queensland Government's Smart Awards 2005 for its efforts towards commercialising a new treatment to fight cancer.
Biosignal to raise $1m in placement
05 August, 2005 by Helen SchullerSydney-based Biosignal (ASX:BOS) has revealed plans to raise AUD$1 million for additional working capital, as it prepares to take its biofilm technology into contact lens clinical trials.
